Holen Sie sich die Stockscreener-App
9.3802
4.07%
0.3002
Schlusskurs vom Vortag:
$9.08
Offen:
$9.31
24-Stunden-Volumen:
39,485
Relative Volume:
0.38
Marktkapitalisierung:
$175.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-10.51%
1M Leistung:
+13.17%
6M Leistung:
+104.55%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.8501
$9.45
1-Wochen-Bereich:
$8.85
$10.69
52-Wochen-Spanne:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Firmenname
Kalaris Therapeutics Inc
Sektor
Branche
Telefon
650-249-2727
Adresse
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
9.3601 | 169.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.68 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.76 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.75 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.55 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.43 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-11-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-23 | Fortgesetzt | Piper Sandler | Neutral |
| 2025-05-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kalaris Therapeutics Inc Aktie (KLRS) Neueste Nachrichten
KLRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kalaris Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
KLRS Should I Buy - Intellectia AI
Published on: 2026-02-28 06:52:09 - baoquankhu1.vn
ETFs Investing in Kalaris Therapeutics, Inc. Stocks - TradingView
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold - MarketBeat
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therape - GuruFocus
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therapeutics Inc - GuruFocus
Sell Signal: Is CRISPR Therapeutics AG backed by strong institutional buyingGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Kalaris Therapeutics Insider Bought Shares Worth $5,000,006, According to a Recent SEC Filing - marketscreener.com
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock - MarketBeat
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares By Investing.com - Investing.com South Africa
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares - Investing.com Australia
Akkaraju group reports 56.5% Kalaris (KLRS) ownership stake - Stock Titan
RTW discloses 5.7% Kalaris Therapeutics (KLRS) ownership stake - Stock Titan
Earnings Miss: How Kalaris Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Action & Weekly Market Pulse Alerts - mfd.ru
Is Kalaris Therapeutics Inc. undervalued by DCF analysisSwing Trade & Capital Efficiency Focused Ideas - mfd.ru
Will Kalaris Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Kalaris Therapeutics raises $50M privately - MSN
What’s the MACD signal for Kalaris Therapeutics Inc.Double Top/Bottom Patterns & High Return Capital Strategies - bollywoodhelpline.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Block Trades: Can Kalaris Therapeutics Inc weather a recessionWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Swing Trade: Is Kalaris Therapeutics Inc. affected by consumer sentimentInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
How Kalaris Therapeutics Inc. stock responds to policy changesMarket Sentiment Report & Technical Pattern Based Buy Signals - Улправда
Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - Улправда
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Finanzdaten der Kalaris Therapeutics Inc-Aktie (KLRS)
Es liegen keine Finanzdaten für Kalaris Therapeutics Inc (KLRS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):